Leaderboards/Lipoproteins and Cardiovascular Health

Lipoproteins and Cardiovascular Health

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Camilla Ditlev Lindhardt Johannesen
University of Copenhagen
2
Tamar I. de Vries
Heidelberg University
3
Yannick Kaiser
Amsterdam University Medical Centers
4
Roger S. Blumenthal
Unknown
5
Tycho R. Tromp
St. Antonius Ziekenhuis
6
Joanna Lewek
Medical University of Lodz
7
Sining Xie
University of Milan
8
Omar Mhaimeed
Johns Hopkins Hospital
9
Giosiana Bosco
Università degli Studi di Enna Kore
10
Paulina Stürzebecher
University Hospital Leipzig

Papers

1
Publication in American Journal of Preventive Cardiology (2024) [103 citations, W4392906909]
American Journal of Preventive Cardiology|2024
103 cit.
2
Dyslipidaemia management in pregnant patients: a 2024 update
European Heart Journal Open|2024
58 cit.
3
Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials
Cardiovascular Research|2024
56 cit.
4
Excess Apolipoprotein B and Cardiovascular Risk in Women and Men
Journal of the American College of Cardiology|2024
56 cit.
5
Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials
Atherosclerosis|2025
18 cit.
6
Publication in The Lancet Regional Health - Europe (2024) [14 citations, W4400204778]
The Lancet Regional Health - Europe|2024
14 cit.
7
Publication in Pediatric Research (2024) [12 citations, W4392242968]
Pediatric Research|2024
12 cit.
8
Publication in American Journal of Preventive Cardiology (2025) [6 citations, W4408076759]
American Journal of Preventive Cardiology|2025
6 cit.
9
Clinical reality and challenges with familial hypercholesterolemia patients' management. 2024 results from the Regional Center for Rare Diseases (RCRD) Registry in Poland
International Journal of Cardiology|2024
4 cit.
10
Publication in Current Opinion in Lipidology (2024) [3 citations, W4393253130]
Current Opinion in Lipidology|2024
3 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Riyaz Patel
University College London
2
Ann Marie Návar
The University of Texas Southwestern Medical Center
3
Alena Grebe
University of Massachusetts Chan Medical School
4
Mohamed B. Elshazly
Menoufia University
5
Scott M. Damrauer
Philadelphia VA Medical Center
6
Mark Chaffin
Broad Institute
7
Mark A McClanahan
Unknown
8
Marlou L. Dirks
University of Exeter
9
Lu-Shan Liu
Capital Medical University
10
Martina De Marco
Pontificia Universidad Católica de Chile

Papers

1
Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy
Nature|2022
392 cit.
2
Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020
Journal of the American Heart Association|2022
182 cit.
3
Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice
JAMA Cardiology|2022
67 cit.
4
Genome-wide association study of thoracic aortic aneurysm and dissection in the Million Veteran Program
Nature Genetics|2023
62 cit.
5
Major Depressive Disorder Impacts Peripheral Artery Disease Risk Through Intermediary Risk Factors
Journal of the American Heart Association|2024
62 cit.
6
Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients
Circulation Cardiovascular Quality and Outcomes|2023
53 cit.
7
Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study
Cardiovascular Diabetology|2022
41 cit.
8
Common-variant and rare-variant genetic architecture of heart failure across the allele-frequency spectrum
Nature Genetics|2025
29 cit.
9
Short‐term disuse does not affect postabsorptive or postprandial muscle protein fractional breakdown rates
Journal of Cachexia Sarcopenia and Muscle|2023
19 cit.
10
Achievement of LDL-C <55 mg/dL among US adults: Findings from the cvMOBIUS2 registry
American Heart Journal|2024
19 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Peter W.F. Wilson
VA Tennessee Valley Healthcare System
2
Eugene Braunwald
Mass General Brigham
3
John J.P. Kastelein
QRx Pharma (United States)
4
Helen H. Hobbs
Southwestern Medical Center
5
Robert J. Glynn
Brigham and Women's Hospital
6
Antonio M. Gotto
Cornell University
7
Linda Van Horn
Unknown
8
Børge G. Nordestgaard
Gentofte Hospital
9
Ernst J. Schaefer
Tufts University
10
Michael Gnant
Austrian Breast & Colorectal Cancer Study Group

Papers

1
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Civil War Book Review|2002
12.2k cit.
2
Prediction of Coronary Heart Disease Using Risk Factor Categories
Circulation|1998
9.6k cit.
3
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
The Lancet|1994
8.5k cit.
4
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
The Lancet|1998
8.4k cit.
5
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
New England Journal of Medicine|1996
7.5k cit.
6
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Circulation|2013
7.1k cit.
7
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
New England Journal of Medicine|2008
6.6k cit.
8
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels
JAMA|1998
5.3k cit.
9
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Journal of the American College of Cardiology|2013
5k cit.
10
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Journal of the American College of Cardiology|2013
3.9k cit.

Reagents for Lipoproteins and Cardiovascular Health

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 65

Phospho-HS1 (Tyr378/397) (D12C1) Rabbit Monoclonal Antibody

Cited in 6 papers
#8714$179,446
View Evidence →
Cell Signaling TechnologyEvidence 67

WSTF Antibody

Cited in 6 papers
#2152$317
View Evidence →
Cell Signaling TechnologyEvidence 65

Stat3 (D1B2J) Rabbit Monoclonal Antibody

Cited in 6 papers
#30835$167,366
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 67

Vimentin (D21H3) Rabbit Monoclonal Antibody (APC Conjugate)

Cited in 14 papers
#95159$465
View Evidence →
Cell Signaling TechnologyEvidence 63

MAP2 (D5G1) Rabbit Monoclonal Antibody

Cited in 7 papers
#8707$161,384
View Evidence →
Cell Signaling Technology

SignalSilence® Akt siRNA I

Cited in 6 papers
#6211$381
View Evidence →